ArticleMikrochimica acta2026
Biomimetic PtPd nanozyme induce glutamylcysteine synthetase inhibition for enhanced radioimmunotherapy.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multifunctional CuFrontiers in chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
A multi pathway enhanced radiotherapeutic strategy is presented that combines PtPd nanozyme-based reactive oxygen species (ROS) amassment with the inhibition of glutathione (GSH) synthesis mediated by L-buthionine sulfoximine (BSO). To this end a (BSO)-loaded biomimetic PtPd nanozyme system (named CPB) coated with cancer cell membrane (CM) was developed for radiotherapy (RT) sensitization and immunogenic cell death (ICD). The CM guides nanoparticles to specifically bind tumor cells via homologous targeting, and serves as an efficient carrier for BSO, preventing leakage in blood circulation and enabling precise BSO release in tumors. Then, BSO block both the substrate and enzymatic pathways critical for GSH production by inhibiting glutamylcysteine synthetase (γ-GCS). PtPd nanozyme could amplify oxidative stress in tumor microenvironment (TME) by catalyzing hydrogen peroxide to produce hydroxyl radical (·OH). Furthermore, the presence of Pt and Pd in CPB can enhance local RT energy deposition in tumor site. Both in vitro and in vivo experiments showed CPB significantly inhibiting tumor growth with good biocompatibility. This study underscores that robust RT sensitization is attainable by means of inhibiting γ-GCS synthesis while boosting the production of ROS.
Indexed as
Identifiers
41951978What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.